Preclinical pharmacokinetics, manufacturing, and safety studies supporting a multicenter cancer gene therapy trial

Hum Gene Ther. 1995 May;6(5):549-50. doi: 10.1089/hum.1995.6.5-549.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Clinical Trials as Topic*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • DNA*
  • DNA, Recombinant
  • Genetic Therapy* / adverse effects
  • HLA-B7 Antigen / biosynthesis
  • HLA-B7 Antigen / genetics
  • Humans
  • Lipids / adverse effects
  • Lipids / pharmacokinetics
  • Lipids / therapeutic use*
  • Multicenter Studies as Topic*
  • Neoplasms / therapy*
  • Plasmids / adverse effects
  • Plasmids / genetics
  • Plasmids / pharmacokinetics
  • Plasmids / therapeutic use*
  • beta 2-Microglobulin / biosynthesis
  • beta 2-Microglobulin / genetics

Substances

  • Allovectin-7
  • DNA, Recombinant
  • HLA-B7 Antigen
  • Lipids
  • beta 2-Microglobulin
  • DNA